Explore ViiV Healthcare
Medicines in Development
ViiV Healthcare is committed to developing new medicines for HIV to reduce its impact on the more than 1.1 million people in the US living with the virus.1 Our scientists and researchers continue to work to identify new ways to lessen the burden not only of the disease, but also of daily treatment of HIV.
Clinical development pipeline
INSTI = integrase strand transfer inhibitor; LA = long-acting
- Centers for Disease Control and Prevention. Estimated HIV incidence and prevalence in the United States, 2010–2016. HIV Surveillance Supplemental Report 2019;24(No. 1). Table 7, page 47. Available at: https://www.cdc.gov/hiv/pdf/library/reports/surveillance/cdc-hiv-surveillance-supplemental-report-vol-24-1.pdf. Last accessed November 2019.
Website images are not intended to imply that the models pictured have HIV.